NOG Protein (C-human IgG1-Fc, Mouse)

1.Measured by its ability to inhibit BMP4-induced alkaline phosphatase production by MC3T3-E1 cells. The ED50 for this effect is typically 0.1-0.6μg/mL. 2.Human intestinal cancer organoids were cultured with RSPO1 (Cat#11083-HNAS), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 3.Human colorectum organoids were cultured with RSPO1 (Cat#11083-HNAS), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 4.Human lung cancer organoids were cultured with FGF2 (Cat#10014-HNAE), FGF4 (Cat#16043-HNAE), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 5.Human lung organoids were cultured with FGF2 (Cat#10014-HNAE), FGF4 (Cat#16043-HNAE), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 6.Human cholangiocarcinomas organoids were cultured with FGF2 (Cat#10014-HNAE), HGF (Cat#10463-HNAS), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 7.Human liver cancer organoids were cultured with FGF2 (Cat#10014-HNAE), HGF (Cat#10463-HNAS), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), TGFB1 (Cat#10804-HNAC), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 8.Human kidney cancer organoids were cultured with FGF2 (Cat#10014-HNAE), FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 9.Human kidney organoids were cultured with FGF7 (Cat#10210-H07E), EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS), HGF (Cat#10463-HNAS), FGF4 (Cat#16043-HNAE) . (Routinely tested) . Data provided by D1 Medical Technology. 10.Human gastric cancer organoids were cultured with EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 11.Human stomach organoids organoids were cultured with EGF (Cat#50482-MNCH), FGF10 (Cat#10573-HNAE), NOG (Cat#50688-M02H), RSPO1 (Cat#11083-HNAS) . (Routinely tested) . Data provided by D1 Medical Technology. 12.Human breast cancer organoids were cultured with FGF7 (Cat#10210-H07E), RSPO1 (Cat#11083-HNAS), IGF1 (Cat#10598-HNAE), EGF (Cat#50482-MNCH), NRG1 Beta 1 (Cat#11609-H01H), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 13.Human ovarian organoids were cultured with IGF1 (Cat#10598-HNAE), NRG1 Beta 1 (Cat#11609-H01H), RSPO1 (Cat#11083-HNAS), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology. 14.Human small intestinal organoids were cultured with IL22 (Cat#13059-HNAE), FGF10 (Cat#10573-HNAE), EGF (Cat#50482-MNCH), NOG (Cat#50688-M02H) . (Routinely tested) . Data provided by D1 Medical Technology.

The recombinant mouse NOG/Fc comprises 454 amino acids and has a predicted molecular mass of 51 kDa. It migrates as approximately 60 kDa band in SDS-PAGE under reducing conditions.